F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.
Sirtex has been ordered to turn over information related to a possible acquisition to law firm Maurice Blackburn, which is leading a shareholder class action against the life sciences company.
A class action against Johnson & Johnson unit Ethicon over allegedly faulty pelvic mesh implants is once more vying for an expanded group definition ahead of settlement talks as the clock ticks down to judgment.
AFT Pharmaceuticals has accused rival Reckitt Benckiser of using the court as a “clearance house” to beat its competitors, the latest development in a long-running dispute over AFT’s Maxigesic ads.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan’s request for an order blocking Sun from launching its own generic version of the drug.
An appeals court has dismissed a banned medical doctor’s challenge to the granting of three vexatious proceedings orders on constitutional grounds that the judge who made the orders was too old.
In a first for the NSW Supreme Court, Judge Peter Garling last week found that the plaintiff in a class action does not need to have a claim against all defendants, a case that could make life much easier for plaintiff lawyers, says barrister Daniel Meyerowitz-Katz of Second Floor Wentworth Chambers.clas